3 ms·
This is a fairly even and well thought out piece but the author does seem to be a fan of 23andme: the author suggests that the FDA should have contacted 23andme
by kghose 13y ago
This is a fairly even and well thought out piece but the author does seem to be a fan of 23andme: the author suggests that the FDA should have contacted 23andme semi-formally before because 23andme has a high turnover and their senior management is having a tough personal time. This is a bit funny. The author is basically suggesting that the management of 23andme is incompetent and the FDA needs to make allowances for this incompetence.
Otherwise the article nicely lays out the tensions between consumer advocacy, scientific rigor and sales.
- AsymetricCom 13y agoIt's clear that 23 thinks that the FDA is incapable of enforcing their mandate and is daring them to do something about it in the media. This is just more BS spin to try to justify their bold and reckless PR maneuvering, under the guise of super-important and helpful medical technology being held back by big bad careless government regulation. I hope 23 continues to pretend like it does nothing wrong in the boardroom, while playing the media through their Google trumpet.
- fudgekludge 13y agoIt seems as though the author may be making up for some embarrassment on the part of the editors for putting 23 on the cover of fast company recently.
- macspoofing 13y agoFastcompany and its editors are not at fault here. It's up to 23andMe to be prepared.